Kevin M. Flanigan, MD | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Healthcare Providers

Kevin M. Flanigan, MD

Healthcare Provider
Director
Center for Gene Therapy, The Research Institute
Nationwide Children’s Hospital
700 Children's Drive
Columbus, Ohio, United States

Kevin M. Flanigan, MD, is an attending neurologist at Nationwide Children’s and Professor of Pediatrics and Neurology at The Ohio State University College of Medicine. Certified by the American Board of Psychiatry and Neurology, Dr. Flanigan is director of the Center for Gene Therapy in The Research Institute at Nationwide Children’s and a leading expert in neuromuscular disorders. He is also on the physician team for Nationwide Children’s world-class Neuromuscular Disorders program, which provides coordinated care with pediatric experts from more than a dozen specialties.

Dr. Flanigan earned his medical degree from Rush Medical College and completed his internship at the University of Michigan Health System before completing his Neurology residency and fellowship in Neuromuscular Disorders at the Johns Hopkins Hospital, and an additional post-doctoral laboratory fellowship in Human Molecular Biology and Genetics at the University of Utah.

His primary research interest is in the genetic and molecular characterization of inherited neuromuscular diseases, and the development of therapies directed toward these diseases. A major focus of his laboratory concerns genotype/phenotype correlation in, with the intention of increasing our understanding of the pathogenesis in this disease and translating this understanding into improved therapies.

 

Representative Publications:

Developing standardized corticosteroid treatment for Duchenne muscular dystrophy

Ataluren: An Overview of Clinical Trial Results in Nonsense Mutation Duchenne Muscular Dystrophy

Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial

rareRelated